OCTO-TELEMATICS
6.12.2022 15:01:35 CET | Business Wire | Press release
OCTO Telematics, the leader in data analytics for the insurance sector, Smart Mobility and Fleet Management, announced today the opening of a new office in Tokyo, Japan, to strengthen its presence in a strategic hub for technology, robotics and automation. The company was already present in Japan with a commercial partnership with Tokio Marine, a leading insurance company in Japan.
With this announcement OCTO widens its geographical reach, now present in Rome – where the Company Headquarter, Boston, London, Paris, Madrid, Stuttgart, Sao Paulo. Tokyo joins the other six subsidiaries in Hong Kong and Shanghai. The company’s choice to further invest in Asia highlights how the region is an important growth market for the company.
The Japanese subsidiary of OCTO will further help the development of the connected mobility market throughout Japan and surrounding countries, providing technical and sales support to partners.
Thanks to the new subsidiary, OCTO will consolidate the already established presence in a market that has always been innovative in technology, robotics and automation sectors, contributing to Japan’s reputation as a leading manufacturer and exporter of innovative technologies.
The presence of OCTO in Japan will translate into additional opportunities for expanding its core business - advanced telematics and technological solutions for the insurance sector, Fleet Management and Smart Mobility – while also providing sales support to existing and new customers.
OCTO holds the largest global telematics data database, with over 510 billion driving kms collected and 501,000 insurance claims and events analysed with an operational capacity to manage over 400,000 vehicle rentals per month.
“The opening of the new subsidiary in Japan,” said Nicola Veratelli, OCTO Group CEO, “is not a goal but a starting point. Our turnover abroad is constantly growing, and the development of new markets is for us of the utmost importance. This is why Asia is a key market for us, and we expect a significant increase in the coming years as well as opportunities for cultural exchange aimed at developing new solutions tailored to the specific features of the market, that could also be the starting point for the development of innovative solutions in other Countries where OCTO is already operation or will soon be.”
About OCTO
OCTO has always been at the forefront of innovation in the connected mobility sector. A pioneer in insurance telematics, today the company is the main advanced telematics and technology solutions provider also in the Fleet Management and Smart Mobility industries, leveraging Machine Learning and AI to transform IoT data into actionable intelligence.
Thanks to its know-how, the expertise developed in 20 years of global advanced analytical services and its M&A strategy, OCTO is spreading the value of advanced data analytics to serve worldwide end users of different mobile applications with a superior customer experience.
Through different business applications and use cases, OCTO is bringing telematics to the core of smart cities as an advocate of the global goals of sustainability thanks to OCTO Vision Zero: Zero Crashes, Zero Congestion, Zero Pollution.
OCTO has currently 5,5 million connected users, holds the largest global database of telematics data, with more than 510 billion miles of driving data collected and over 501,000 crashes and insurance events analyzed, and an operational management capacity of over 400.000 hires per month.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005051/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom